Avoiding mix-ups

If you are blind or have poor eyesight and cannot read the dose counter on the pen, do not use this pen without help. Get help from a person with good eyesight who is trained to use Tresiba[®].

Always check the insulin label when you receive it at the pharmacy and before each injection to avoid accidental mix-ups between different formulation strengths of Tresiba[®] as well as other insulin products you may be taking.

Using the wrong insulin formulation strength or product could potentially cause you to take too much or too little insulin. Too much insulin can lead to hypoglycaemia, or low blood sugar. Talk to your healthcare provider for more information.

Adverse reactions to Tresiba[®], including medication errors should be reported to Novo Nordisk on 0800 023 2573 or to local authorities.

You can report via:

- The Yellow Card website https://yellowcard.mhra.gov.uk/
- The free Yellow Card app available from the Apple App Store or Google Play Store
- Some clinical IT systems (EMIS, SystmOne, Vision, MiDatabank) for healthcare professionals

Alternatively, you can report a suspected side effect to the Yellow Card scheme by calling 0800 731 6789 for free, Monday to Friday between 9am and 5pm.

Always use this medicine exactly as your doctor has told you. Follow all instructions in the package leaflet. Check with your healthcare provider, pharmacist or nurse if you need help.

Who should not take Tresiba®

The contraindications for the use of Tresiba[®] are included on the label. If you have any queries regarding this information, please discuss with your healthcare professional.



Tresiba[®] (insulin degludec)

Understanding the formulation strength your healthcare provider has prescribed



What Tresiba® is and what it is used for

Tresiba[®] is a once-daily basal analogue insulin. Tresiba[®] is used to treat diabetes mellitus in adults, adolescents and children from 1 year.¹ It helps your body reduce your blood sugar level. Tresiba[®] is used for once-daily dosing. For occasions when you cannot follow your regular dosing schedule you can change the time of dosing. Always ensure a minimum of 8 hours between injections.

Two Tresiba® formulation strengths

Tresiba[®] comes in two formulation strengths: 100 units/mL and 200 units/mL. Tresiba[®] 200 units/mL FlexTouch[®] pen has twice as many insulin units in each mL. Your healthcare provider will prescribe the formulation strength that is right for you.

Both devices have a dose counter window that shows the exact dose dialled. This means that the dose shown in the window is the dose that will be delivered regardless of formulation strength. Always use the dose counter to select the dose. **Do not count clicks. Dose conversion should not be done if you move from one formulation strength to another.** Check how many units were selected before injecting Tresiba[®]. Never use a syringe to withdraw insulin from the pen or use the cartridge outside of the FlexTouch[®] pen.

Tresiba®

Tresiba[®] h 200 units/mL formulation strength

Dark green

100 units/mL formulation strength 80 units max dose per injection



Holds 300 units of insulin in 3 mL

Holds 600 units of insulin in 3 mL

160 units max dose per injection

units/mL

Recognising your prescribed strength

It is important to be sure you are using the correct formulation strength prescribed by your healthcare provider. "Tresiba® 100 units/mL" or "Tresiba® 200 units/mL" is clearly marked on the pen label and packaging.


Additionally, Tresiba[®] 100 units/mL packaging and label are light green, and Tresiba[®] 200 units/mL packaging and label are dark green with striping. The Tresiba[®] 200 units/mL label and packaging also have a red box highlighting the formulation strength.

Tresiba® 100 units/mL package 5 pens per carton

Tresiba[®] 200 units/mL package 3 pens per carton



Solution for injection in pre-filled pen insulin degludec





...

Tresiba® 100 units/mL Tresiba® 200 units/mL